Limited induction of SARS-CoV-2-specific T cell responses in children with multisystem inflammatory syndrome compared with COVID-19

JCI Insight. 2022 Feb 22;7(4):e155145. doi: 10.1172/jci.insight.155145.

Abstract

Why multisystem inflammatory syndrome in children (MIS-C) develops after SARS-CoV-2 infection in a subset of children is unknown. We hypothesized that aberrant virus-specific T cell responses contribute to MIS-C pathogenesis. We quantified SARS-CoV-2-reactive T cells, serologic responses against major viral proteins, and cytokine responses from plasma and peripheral blood mononuclear cells in children with convalescent COVID-19, in children with acute MIS-C, and in healthy controls. Children with MIS-C had significantly lower virus-specific CD4+ and CD8+ T cell responses to major SARS-CoV-2 antigens compared with children convalescing from COVID-19. Furthermore, T cell responses in participants with MIS-C were similar to or lower than those in healthy controls. Serologic responses against spike receptor binding domain (RBD), full-length spike, and nucleocapsid were similar among convalescent COVID-19 and MIS-C, suggesting functional B cell responses. Cytokine profiling demonstrated predominant Th1 polarization of CD4+ T cells from children with convalescent COVID-19 and MIS-C, although cytokine production was reduced in MIS-C. Our findings support a role for constrained induction of anti-SARS-CoV-2-specific T cells in the pathogenesis of MIS-C.

Keywords: Adaptive immunity; COVID-19; Cellular immune response; Peptides.

Publication types

  • Research Support, N.I.H., Extramural
  • Research Support, Non-U.S. Gov't

MeSH terms

  • Adolescent
  • COVID-19 / complications*
  • COVID-19 / immunology
  • Child
  • Child, Preschool
  • Female
  • Humans
  • Male
  • SARS-CoV-2 / immunology*
  • Systemic Inflammatory Response Syndrome / immunology*
  • T-Lymphocytes / immunology*

Supplementary concepts

  • pediatric multisystem inflammatory disease, COVID-19 related

Grants and funding

FastGrant Program from Emergent Ventures at the Mercatus Center at George Mason University and Genentech